We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+12.09%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.04B
AUM Growth
+$139M
Cap. Flow
+$195M
Cap. Flow %
9.6%
Top 10 Hldgs %
52.83%
Holding
78
New
7
Increased
4
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$101M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.1M
3
RVMD icon
Revolution Medicines
RVMD
+$17.2M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.2M
5
ELVN icon
Enliven Therapeutics
ELVN
+$14.5M

Top Sells

Rank Stock Value
1
GERN icon
Geron
GERN
+$19.6M
2
ARVN icon
Arvinas
ARVN
+$5.13M
3
FATE icon
Fate Therapeutics
FATE
+$4.53M
4
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$638K
5
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$41K

Sector Composition

Rank Sector Weight
1 Healthcare 99.75%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
76
Arvinas
ARVN
$518M
– –
-150,000
Closed -$5.13M
GERN icon
77
Geron
GERN
$828M
– –
-8,100,000
Closed -$19.6M
BLCM
78
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-56,950
Closed -$41K
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Boxer Capital held 78 positions worth $2.04B, up 7.3% from $1.9B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Boxer Capital deployed $195M of net new capital in Q1 2023, opening 7 new positions and adding to 4 existing holdings. Its largest new stake was Sarepta Therapeutics: 775,000 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Fate Therapeutics, an estimated $4.53M trimmed.

  • Boxer Capital's largest Q1 2023 buy was Sarepta Therapeutics: 775,000 shares worth $107M.
  • Boxer Capital added most to Revolution Medicines in Q1 2023, an estimated $17.2M increase.
  • Boxer Capital's biggest Q1 2023 reduction was Fate Therapeutics, cutting an estimated $4.53M.
  • Boxer Capital fully exited Geron in Q1 2023, selling an estimated $19.6M.
  • Boxer Capital's ten largest holdings make up 53% of its $2.04B portfolio in Q1 2023.
  • Boxer Capital opened 7 new positions and closed 3 in Q1 2023.
  • Boxer Capital's portfolio value rose 7.3% quarter-over-quarter to $2.04B.

Based on Boxer Capital's 13F filing for Q1 2023, filed 15 May 2023.